Promises and Pitfalls of In Vivo CAR Gene Therapy: Clinical Proof-of-Concept Progresses Amidst Focus on Safety and Biological Factors

August 9, 2026

Blood – ASH Publications USA

Overview

While ex vivo CAR-T cell therapies demonstrate high efficacy in lymphoid hematologic malignancies, their logistical complexity and high costs limit patient access. In contrast, in vivo CAR gene therapy, which aims to generate CAR-expressing T cells within the body, presents a promising yet challenging alternative. Recent clinical reports offer proof-of-concept for the feasibility and therapeutic potential of in vivo CAR gene delivery, but critical technical, biological, and safety considerations are under active discussion. Successful development could dramatically enhance CAR-T therapy accessibility.

In Depth

Key Findings

In vivo CAR gene therapy holds the potential to circumvent the manufacturing complexities and logistical challenges associated with conventional ex vivo CAR-T cell therapies by generating CAR (Chimeric Antigen Receptor)-expressing T cells directly within the patient’s body. Recent clinical reports provide proof-of-concept for the feasibility and therapeutic potential of in vivo CAR gene delivery, though its implementation is accompanied by unique technical, biological, and safety considerations.

Technical / Clinical Details

Ex vivo CAR-T cell therapy involves collecting a patient’s T cells, genetically modifying them outside the body, massively expanding them, and then reinfusing them back into the patient. While this process ensures stringent quality control, it is constrained by long manufacturing timelines, high costs, and the need for specialized facilities. In contrast, in vivo CAR gene therapy administers CAR-encoding genes directly into the patient’s body, typically via vectors such as adeno-associated viruses (AAV), to convert endogenous T cells into CAR-expressing T cells in situ. This approach could significantly simplify the manufacturing process, reduce treatment costs, and enable broader accessibility in more healthcare settings. Initial clinical reports have shown successful proof-of-concept, with CAR-expressing T cell generation and disease responses observed in some patients treated with in vivo CAR gene therapy. However, significant challenges remain, including vector targeting specificity, potential systemic toxicity, ensuring adequate in vivo CAR-T cell expansion and persistence, and managing immunogenic responses. Overcoming these hurdles requires more precise vector design, optimized routes of administration, and sophisticated immune control strategies.

Background & Context

CAR-T cell therapy has achieved revolutionary success in treating lymphoid hematologic malignancies, but its accessibility limitations have been a consistent point of contention. In vivo CAR gene therapy is gaining substantial attention as a next-generation approach to dismantle these access barriers and extend the benefits of CAR-T treatment to a broader patient population. The potential for improved efficacy in solid tumors and reduced off-target toxicity are significant aspirations for in vivo approaches. Research and development investments in this area are vigorous, with multiple biotechnology companies and academic institutions actively pursuing clinical trials.

Strategic Significance & Outlook

The progression of in vivo CAR gene therapy is poised to significantly influence the future of CAR-T cell therapies. Future research will focus on further enhancing vector safety and efficiency, minimizing systemic side effects, and achieving desired T cell activation and persistence. Critically, the accumulation of long-term safety and efficacy data from ongoing clinical trials is indispensable. If these challenges are resolved, in vivo CAR gene therapy could transcend the current limitations of CAR-T cell therapies, becoming a more accessible and widespread treatment for cancer, and potentially expanding to autoimmune diseases, marking a truly transformative advancement in medicine. This evolution will accelerate the overall development of the regenerative medicine and gene therapy fields.

Source: https://ashpublications.org/blood/article/148/5/535/568623/Promises-and-potential-pitfalls-of-in-vivo-CAR

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.